Interleukin 6 and complement serum level study in Parkinson's disease
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F18%3A00068907" target="_blank" >RIV/00159816:_____/18:00068907 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216224:14740/18:00103549
Výsledek na webu
<a href="http://dx.doi.org/10.1007/s00702-018-1857-5" target="_blank" >http://dx.doi.org/10.1007/s00702-018-1857-5</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00702-018-1857-5" target="_blank" >10.1007/s00702-018-1857-5</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Interleukin 6 and complement serum level study in Parkinson's disease
Popis výsledku v původním jazyce
The objective of this study is to assess whether elevation of serum inflammatory markers levels may indicate the progression of clinical impairment in Parkinson's disease (PD) patients. In 47 PD patients, the serum levels of the C3 and C4 part of the complement and Interleukin-6 (IL-6) were measured. The results at baseline and after 2 years were correlated with scales measuring memory, depression, motor symptoms, and quality of life. Patients with higher levels of C3 and C4 at baseline had decreased quality of life, verbal ability, and memory. Patients with higher IL-6 at baseline showed worse depression scores at 2 years. Patients with persistently higher levels of C3 and C4 at 2 years had worse quality of life and memory ability. Uncorrected p values are reported due to the exploratory nature of the study. The results indicate an impact of inflammation on non-motor signs and quality of life in PD. The increase of levels of serum inflammatory biomarkers may indicate the progression of non-motor impairment in PD.
Název v anglickém jazyce
Interleukin 6 and complement serum level study in Parkinson's disease
Popis výsledku anglicky
The objective of this study is to assess whether elevation of serum inflammatory markers levels may indicate the progression of clinical impairment in Parkinson's disease (PD) patients. In 47 PD patients, the serum levels of the C3 and C4 part of the complement and Interleukin-6 (IL-6) were measured. The results at baseline and after 2 years were correlated with scales measuring memory, depression, motor symptoms, and quality of life. Patients with higher levels of C3 and C4 at baseline had decreased quality of life, verbal ability, and memory. Patients with higher IL-6 at baseline showed worse depression scores at 2 years. Patients with persistently higher levels of C3 and C4 at 2 years had worse quality of life and memory ability. Uncorrected p values are reported due to the exploratory nature of the study. The results indicate an impact of inflammation on non-motor signs and quality of life in PD. The increase of levels of serum inflammatory biomarkers may indicate the progression of non-motor impairment in PD.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30210 - Clinical neurology
Návaznosti výsledku
Projekt
<a href="/cs/project/LQ1601" target="_blank" >LQ1601: CEITEC 2020</a><br>
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2018
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Journal of Neural Transmission
ISSN
0300-9564
e-ISSN
—
Svazek periodika
125
Číslo periodika v rámci svazku
5
Stát vydavatele periodika
AT - Rakouská republika
Počet stran výsledku
7
Strana od-do
875-881
Kód UT WoS článku
000430583400010
EID výsledku v databázi Scopus
—